# Every Woman Deserves a Unique Treatment Strategy


AGENDIA®
MAMMAPRINT+BLUEPRINT

**MammaPrint + BluePrint work together to clarify the complexity of overall early-stage breast cancer treatment strategy for each individual patient.**

Rely on definitive results with the most comprehensive genomic profile for breast cancer that **includes molecular subtyping.** With specific guidance, confidently optimize neoadjuvant, adjuvant, or extended adjuvant therapy for each patient, including those that are clinically high-risk. Find clarity every step of the way at **agendia.com**

**MammaPrint, our FDA-cleared test backed by the highest level of clinical evidence, paired with BluePrint, the only commercially available molecular subtyping test, enable you to confidently optimize a unique treatment strategy for each patient.**




### Identify unique molecular subtypes through BluePrint (80-gene assay)

- Determines patients who may benefit from neoadjuvant chemotherapy with an increased likelihood of pathologic complete response (pCR) to inform surgery decisions[1]
- Reveals the 1 in 5 ER+ patients with basal-type breast cancer who may benefit from treatment similar to treatment for triple negative breast cancer[1]
- Identifies patients who may have little response to chemotherapy and may respond to neoadjuvant endocrine therapy[1]

### Optimize treatment strategy through MammaPrint (70-gene assay)

- Predicts chemosensitivity – MammaPrint High Risk results associated with increased likelihood of pCR[1]
- Demonstrates a consistent relative benefit of chemotherapy across clinical trials in MammaPrint High Risk patients (40-50%)[2,3]
- Reclassifies 46% of clinically high risk patients as MammaPrint Low Risk, who may safely avoid chemotherapy[3]
- Identifies patients with an Ultralow Risk of late recurrence (20 yrs) unlikely to benefit from extended endocrine therapy beyond 5 years[4]

### Definitive results for more of your patients with MammaPrint + BluePrint

- Results unaffected by age, pre- or postmenopausal, hormone receptor and nodal status, race, ethnicity, or metabolic syndrome
- The 70-gene assay (MammaPrint®) is the only genomic test with a category 1 National Comprehensive Cancer Network® (NCCN®) recommendation in both LN- and LN+ (0-3 lymph nodes) patients with hormone receptor positive and HER2-negative early stage breast cancer*
- Reports the continuous score as a binary result
- Enables faster decision-making and less patient anxiety with quick turnaround time and user-friendly results
- Developed independently of clinicopathologic factors in untreated patients[5]
- Identifies genes and pathways involved in metastatic recurrence through unbiased gene selection[5]

**Experts recommend use of a single comprehensive genomic profile to inform treatment decisions.**

Choose MammaPrint + BluePrint to optimize treatment strategy for your patients. Visit **agendia.com/everywoman**

AGENDIA®
MAMMAPRINT+BLUEPRINT

References
1. Whitworth P, et al. Ann Surg Oncol. 2017 Mar;24(3):669-75. 2. Knauer M, et al. Breast Cancer Res Treat. 2010 Apr;120(3):655-61.
3. Cardoso F, et al. N Engl J Med. 2016 Aug 25;375(8):717-29.4. Esserman LJ, et al. JAMA Oncol. 2017 Nov 1;3(11):1503-10. 5. van 't Veer LJ, et al. Nature. 2002 Jan 31;415(6871):530-6.

MammaPrint® FFPE is a qualitative in vitro diagnostic test, performed in a central laboratory, using the gene expression profile obtained from formalin-fixed paraffin embedded (FFPE) breast cancer tissue samples to assess a patient's risk for distant metastasis within 5 years. The test is performed for breast cancer patients, with Stage I or Stage II disease, with tumor size ≤ 5.0 cm and lymph node negative. The MammaPrint® FFPE result is indicated for use by physicians as a prognostic marker only, along with other clinico-pathological factors. BluePrint is a laboratory-developed test that was developed, validated and is performed exclusively by Agendia. The test is intended for clinical purposes. The test has not been cleared by the U.S. Food and Drug Administration (FDA) but has been CE-marked for use in Europe. The laboratory is regulated under the Clinical Laboratory Improvement Amendments (CLIA) to ensure the quality and validity of the tests. Our laboratories are CAP- accredited and certified under CLIA to perform high complexity clinical laboratory testing.
*70-gene Assay (MammaPrint) is the only genomic assay with FDA clearance and Level 1 evidence by the American Society of Clinical Oncology (ASCO). 70-Gene Assay (MammaPrint) has a Category 1 recommendation from the National Comprehensive Cancer Network® (NCCN®). Category 1 is based upon high-level evidence; there is uniform NCCN consensus that intervention is appropriate. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Breast Cancer V.1.2019. © 2019 National Comprehensive Cancer Network, Inc 2019. All rights reserved. Accessed May 2019. To view the most recent and complete version of the guidelines, go to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.



M-USA-273-V1 (2019MAY)